Editas Medicine (EDIT) Interest & Investment Income (2015 - 2025)

Editas Medicine (EDIT) has reported Interest & Investment Income for 11 consecutive years, with $1.8 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Interest & Investment Income fell 48.13% year-over-year to $1.8 million; the TTM figure through Sep 2025 stood at $7.8 million (down 56.38% YoY), while the FY2024 annual figure was $14.1 million, down 19.95% from the prior year.
• Interest & Investment Income declined to $1.8 million in Q3 2025 per EDIT's latest filing, from $2.1 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $5.1 million in Q3 2023 and bottomed at $134000.0 in Q1 2021.
• Historically, Interest & Investment Income has averaged $2.3 million across 5 years, with a median of $2.1 million in 2025.
• Annual changes were most pronounced in 2021 — Interest & Investment Income sank 91.4% — and 2022, when it jumped 1449.71%.
• Editas Medicine's Interest & Investment Income stood at $175000.0 in 2021, then surged by 1449.71% to $2.7 million in 2022, then surged by 88.13% to $5.1 million in 2023, then slumped by 76.46% to $1.2 million in 2024, then soared by 52.46% to $1.8 million in 2025.
• Business Quant data shows EDIT's Interest & Investment Income at $1.8 million in Q3 2025, $2.1 million in Q2 2025, and $2.7 million in Q1 2025.